Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays
Due to the beginning of vaccination against COVID-19, serological discrimination between vaccine-associated humoral response and serology-based surveillance of natural SARS-CoV-2 infections as well as breakthrough infections becomes an issue of relevance. Here, we assessed the differentiated effects...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/11/3/426 |
id |
doaj-c54cd162b6e948d59bb45940b2277ead |
---|---|
record_format |
Article |
spelling |
doaj-c54cd162b6e948d59bb45940b2277ead2021-03-04T00:04:15ZengMDPI AGDiagnostics2075-44182021-03-011142642610.3390/diagnostics11030426Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological AssaysAnja Dörschug0Hagen Frickmann1Julian Schwanbeck2Elif Yilmaz3Kemal Mese4Andreas Hahn5Uwe Groß6Andreas E. Zautner7Institute for Medical Microbiology, University Medical Center Göttingen, 37075 Göttingen, GermanyInstitute for Medical Microbiology, Virology and Hygiene, University Medicine Rostock, 18057 Rostock, GermanyInstitute for Medical Microbiology, University Medical Center Göttingen, 37075 Göttingen, GermanyDepartment of Anesthesiology, University Medical Center Göttingen, 37075 Göttingen, GermanyInstitute for Medical Microbiology, University Medical Center Göttingen, 37075 Göttingen, GermanyInstitute for Medical Microbiology, Virology and Hygiene, University Medicine Rostock, 18057 Rostock, GermanyInstitute for Medical Microbiology, University Medical Center Göttingen, 37075 Göttingen, GermanyInstitute for Medical Microbiology, University Medical Center Göttingen, 37075 Göttingen, GermanyDue to the beginning of vaccination against COVID-19, serological discrimination between vaccine-associated humoral response and serology-based surveillance of natural SARS-CoV-2 infections as well as breakthrough infections becomes an issue of relevance. Here, we assessed the differentiated effects of the application of an RNA vaccine using SARS-CoV-2 spike protein epitopes on the results of both anti-spike protein–based serology (EUROIMMUN) and anti-nucleocapsid-based serology (VIROTECH). A total of 80 serum samples from vaccinees acquired at different time points after vaccination was assessed. While positive or borderline serological response in the anti-spike protein assay was observed for all samples (90% both IgG and IgA, 6.3% IgA only, 3.8% borderline IgG only), only a single case of a falsely positive IgM was observed for the anti-nucleocapsid assay as expected due to this assay’s specificity. Positive anti-spike protein antibodies were already detectable in the second week after the first dose of vaccination, with higher titers after the second dose of the vaccine. In conclusion, the combined application of anti-spike protein–based serology and anti-nucleocapsid-based serology will provide a useful option for the discrimination of vaccination response and natural infection.https://www.mdpi.com/2075-4418/11/3/426SARS-CoV-2COVID-19serologyvaccinationsurveillancenucleocapsid |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Anja Dörschug Hagen Frickmann Julian Schwanbeck Elif Yilmaz Kemal Mese Andreas Hahn Uwe Groß Andreas E. Zautner |
spellingShingle |
Anja Dörschug Hagen Frickmann Julian Schwanbeck Elif Yilmaz Kemal Mese Andreas Hahn Uwe Groß Andreas E. Zautner Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays Diagnostics SARS-CoV-2 COVID-19 serology vaccination surveillance nucleocapsid |
author_facet |
Anja Dörschug Hagen Frickmann Julian Schwanbeck Elif Yilmaz Kemal Mese Andreas Hahn Uwe Groß Andreas E. Zautner |
author_sort |
Anja Dörschug |
title |
Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays |
title_short |
Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays |
title_full |
Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays |
title_fullStr |
Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays |
title_full_unstemmed |
Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays |
title_sort |
comparative assessment of sera from individuals after s-gene rna-based sars-cov-2 vaccination with spike-protein-based and nucleocapsid-based serological assays |
publisher |
MDPI AG |
series |
Diagnostics |
issn |
2075-4418 |
publishDate |
2021-03-01 |
description |
Due to the beginning of vaccination against COVID-19, serological discrimination between vaccine-associated humoral response and serology-based surveillance of natural SARS-CoV-2 infections as well as breakthrough infections becomes an issue of relevance. Here, we assessed the differentiated effects of the application of an RNA vaccine using SARS-CoV-2 spike protein epitopes on the results of both anti-spike protein–based serology (EUROIMMUN) and anti-nucleocapsid-based serology (VIROTECH). A total of 80 serum samples from vaccinees acquired at different time points after vaccination was assessed. While positive or borderline serological response in the anti-spike protein assay was observed for all samples (90% both IgG and IgA, 6.3% IgA only, 3.8% borderline IgG only), only a single case of a falsely positive IgM was observed for the anti-nucleocapsid assay as expected due to this assay’s specificity. Positive anti-spike protein antibodies were already detectable in the second week after the first dose of vaccination, with higher titers after the second dose of the vaccine. In conclusion, the combined application of anti-spike protein–based serology and anti-nucleocapsid-based serology will provide a useful option for the discrimination of vaccination response and natural infection. |
topic |
SARS-CoV-2 COVID-19 serology vaccination surveillance nucleocapsid |
url |
https://www.mdpi.com/2075-4418/11/3/426 |
work_keys_str_mv |
AT anjadorschug comparativeassessmentofserafromindividualsaftersgenernabasedsarscov2vaccinationwithspikeproteinbasedandnucleocapsidbasedserologicalassays AT hagenfrickmann comparativeassessmentofserafromindividualsaftersgenernabasedsarscov2vaccinationwithspikeproteinbasedandnucleocapsidbasedserologicalassays AT julianschwanbeck comparativeassessmentofserafromindividualsaftersgenernabasedsarscov2vaccinationwithspikeproteinbasedandnucleocapsidbasedserologicalassays AT elifyilmaz comparativeassessmentofserafromindividualsaftersgenernabasedsarscov2vaccinationwithspikeproteinbasedandnucleocapsidbasedserologicalassays AT kemalmese comparativeassessmentofserafromindividualsaftersgenernabasedsarscov2vaccinationwithspikeproteinbasedandnucleocapsidbasedserologicalassays AT andreashahn comparativeassessmentofserafromindividualsaftersgenernabasedsarscov2vaccinationwithspikeproteinbasedandnucleocapsidbasedserologicalassays AT uwegroß comparativeassessmentofserafromindividualsaftersgenernabasedsarscov2vaccinationwithspikeproteinbasedandnucleocapsidbasedserologicalassays AT andreasezautner comparativeassessmentofserafromindividualsaftersgenernabasedsarscov2vaccinationwithspikeproteinbasedandnucleocapsidbasedserologicalassays |
_version_ |
1724232415853936640 |